Fort Washington Investment Advisors Inc. OH Has $28.30 Million Position in COPT Defense Properties $CDP

Fort Washington Investment Advisors Inc. OH boosted its stake in shares of COPT Defense Properties (NYSE:CDP) by 1.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,017,860 shares of the company’s stock after purchasing an additional 16,346 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned about 0.90% of COPT Defense Properties worth $28,297,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of COPT Defense Properties by 1.2% in the third quarter. Vanguard Group Inc. now owns 16,999,275 shares of the company’s stock worth $493,999,000 after buying an additional 205,143 shares during the last quarter. Alliancebernstein L.P. grew its stake in COPT Defense Properties by 16.8% in the 3rd quarter. Alliancebernstein L.P. now owns 8,457,373 shares of the company’s stock valued at $245,771,000 after buying an additional 1,215,936 shares during the last quarter. JPMorgan Chase & Co. grew its stake in COPT Defense Properties by 7.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,566,073 shares of the company’s stock valued at $103,630,000 after buying an additional 253,558 shares during the last quarter. Channing Capital Management LLC raised its holdings in COPT Defense Properties by 21.0% in the 3rd quarter. Channing Capital Management LLC now owns 2,913,596 shares of the company’s stock worth $84,669,000 after acquiring an additional 506,593 shares during the period. Finally, Bank of America Corp DE raised its holdings in COPT Defense Properties by 5.4% in the 2nd quarter. Bank of America Corp DE now owns 2,577,065 shares of the company’s stock worth $71,075,000 after acquiring an additional 131,287 shares during the period.

Analyst Ratings Changes

CDP has been the subject of a number of recent analyst reports. Citigroup upped their price target on shares of COPT Defense Properties from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, February 10th. Cantor Fitzgerald lifted their price objective on COPT Defense Properties from $33.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, February 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of COPT Defense Properties in a research report on Wednesday, January 21st. Truist Financial raised their target price on COPT Defense Properties from $31.00 to $33.00 and gave the company a “hold” rating in a report on Tuesday, March 3rd. Finally, Jefferies Financial Group lifted their price target on COPT Defense Properties from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.88.

Insider Buying and Selling at COPT Defense Properties

In other news, Director Philip L. Hawkins sold 5,536 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $32.71, for a total transaction of $181,082.56. Following the sale, the director directly owned 15,188 shares in the company, valued at approximately $496,799.48. The trade was a 26.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.42% of the company’s stock.

COPT Defense Properties Price Performance

Shares of COPT Defense Properties stock opened at $30.63 on Friday. The company has a debt-to-equity ratio of 1.77, a current ratio of 3.95 and a quick ratio of 3.95. The company has a market cap of $3.47 billion, a PE ratio of 22.69 and a beta of 0.86. The firm has a fifty day moving average price of $31.54 and a two-hundred day moving average price of $29.94. COPT Defense Properties has a fifty-two week low of $23.92 and a fifty-two week high of $32.82.

COPT Defense Properties (NYSE:CDP) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. COPT Defense Properties had a net margin of 19.94% and a return on equity of 9.82%. The business had revenue of $197.36 million during the quarter, compared to analyst estimates of $188.79 million. During the same quarter in the prior year, the business earned $0.65 earnings per share. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. COPT Defense Properties has set its FY 2026 guidance at 2.710-2.790 EPS and its Q1 2026 guidance at 0.670-0.690 EPS. Analysts expect that COPT Defense Properties will post 2.67 EPS for the current year.

COPT Defense Properties Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Tuesday, March 31st will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, March 31st. This is a boost from COPT Defense Properties’s previous quarterly dividend of $0.31. COPT Defense Properties’s payout ratio is 90.37%.

COPT Defense Properties Profile

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.